Table 1.
Target therapeutic areas and main metabolic enzymes targeted in general global clinical trials (GCTs) and Asian GCTs
| General GCTs (90 drugs) | Asian GCTs (31 drugs) | Total (121 drugs) | ||
|---|---|---|---|---|
| Target therapeutic area | Neoplasms | 33 (36.7) | 6 (19.4) | 39 (32.2) |
| Endocrine, nutritional, and metabolic diseases | 14 (15.6) | 6 (19.4) | 20 (16.5) | |
| Diseases of the respiratory system | 12 (13.3) | 1 (3.2) | 13 (10.7) | |
| Diseases of the blood and blood‐forming organs, and certain disorders involving immune mechanisms | 8 (8.9) | 0 (0.0) | 8 (6.6) | |
| Diseases of the circulatory system | 7 (7.8) | 1 (3.2) | 8 (6.6) | |
| Diseases of the eye and adnexa | 5 (5.6) | 1 (3.2) | 6 (5.0) | |
| Diseases of the nervous system | 4 (4.4) | 3 (9.7) | 7 (5.8) | |
| Certain infectious and parasitic diseases | 2 (2.2) | 3 (9.7) | 5 (4.1) | |
| Mental and behavioral disorders | 1 (1.1) | 5 (16.1) | 6 (5.0) | |
| Diseases of the genitourinary system | 0 (0.0) | 2 (6.5) | 2 (1.7) | |
| Other diseases | 4 (4.4) | 3 (9.7) | 7 (5.8) | |
| Metabolic enzyme | None | 38 (42.2) | 12 (38.7) | 50 (41.3) |
| CYP3A | 29 (32.2) | 4 (12.9) | 33 (27.3) | |
| UDP‐glucuronosyltransferases (UGTs) | 10 (11.1) | 5 (16.1) | 15 (12.4) | |
| CYP2D6 | 4 (4.4) | 4 (12.9) | 8 (6.6) | |
| Multiple CYP isoenzymes | 4 (4.4) | 0 (0.0) | 4 (3.3) | |
| CYP2C8 | 2 (2.2) | 0 (0.0) | 2 (1.7) | |
| CYP2C19 | 1 (1.1) | 1 (3.2) | 2 (1.7) | |
| CYP1A2 | 1 (1.1) | 1 (3.2) | 2 (1.7) | |
| Other enzymes | 1 (1.1) | 4 (12.9) | 5 (4.1) |
Numbers in parentheses denote percentages.